Toft Group Completes Executive Search for OPKO Health, Inc. (Nasdaq: OPK) in Miami, FL


Executive search firm Toft Group has placed Mr. Jim DeMarco as North American Sales Director, Diagnostics at OPKO Health, Inc. in Miami, FL. Most recently serving as Managing Partner at Remedy Group in Princeton, NJ., Mr. DeMarco brings more than 30 years of commercial pharmaceutical experience which has led to increasing responsibility in successfully building and leading several broad and specialty operations with established large companies such as Schering Plough, Amgen, Eisai, as well as emerging companies like Idenix, Myriad Pharma, BD Rx, and Intercept.

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, a treatment pending FDA approval for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation approved by FDA and launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy.